Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours.
about
Parathyroid cancerDiscovery of transcriptional regulators and signaling pathways in the developing pituitary gland by bioinformatic and genomic approaches.Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis.Update on genetic and clinical aspects of primary hyperparathyroidism.Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kineticsDeletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice.The molecular pathogenesis and management of bronchial carcinoids.Molecular profiling in primary hyperparathyroidism.Molecular diagnosis of parathyroid carcinoma: a reality in the near future.Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36.Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia.Defining a molecular phenotype for benign and malignant parathyroid tumors.Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.The molecular genetics of endocrine tumours.Somatic mutation of the MEN1 gene in parathyroid tumours.A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer.Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinomaMutational Analyses of Connexin 26, Connexin 30 and Connexin 46 as Candidate Tumor Suppressor Genes in Parathyroid Carcinoma
P2860
Q26796612-CBAEBD82-0FF4-43B4-A422-3FF3AB5B6EADQ33397184-CB9C53B0-E438-42E0-9003-13B625D36AFCQ34569319-24629370-B7C7-404D-9284-40B93E9A8827Q35583393-1788C22A-C01D-495D-AE60-985E7FFFEBD3Q35583695-B8CA5274-1ADE-463B-8E1B-EB3127710409Q35842080-E7ECF6C0-4C65-43A3-8456-CF90BBE2C592Q36455160-9E2FCF91-630C-428D-9F7E-549B9983CF04Q37833109-BC3F259C-A1C5-449A-9944-4A130F4EF6FAQ38193373-37923854-B3B3-46E6-AD37-39CADE23FF6EQ39670916-DA377AF3-44DB-45C6-AF2D-A718F2856C0FQ42273863-9425CB31-9B36-423C-BE63-874444333C63Q42807625-CD21F356-8940-4577-B26F-F3A5301E4C1CQ44557302-1AE2DC70-FAC9-4273-A253-01328C325FF2Q45907440-2FC0959D-333C-4F3B-856E-27A40541189FQ47920723-B3ACEAE2-9BB5-46C1-AA70-9AB7D5C30FEAQ50623754-E84BC8F0-B653-416A-9ECE-D1517D193D3DQ54737286-95F81F21-1A82-4B51-855E-641255819E2AQ56915453-11E0654A-7A67-4BE7-AAA0-75D819D69CF9Q56915561-463C206F-07CC-41B9-8B60-F17B5B552E24
P2860
Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@en
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@nl
type
label
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@en
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@nl
prefLabel
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@en
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@nl
P2093
P1476
Loss of heterozygosity studies ...... creatic and carcinoid tumours.
@en
P2093
P304
P356
10.1046/J.1365-2265.1996.D01-1561.X
P577
1996-08-01T00:00:00Z